Avsnitt
-
Rod Wong and Stephanie Sirota delve into the transformative potential of GLP-1 drugs, focusing on their impact on obesity and related diseases. Rod shares his insights into the next generation of obesity therapies and the opportunities they present for innovation and investment in the biotech sector.
PODCAST TEAM
Producer: Devon Leaver
Editor: Dominique Guerra
Featuring: Rod Wong, moderated by Stephanie Sirota, Chief Business Officer, and Partner at RTW Investments.
Stay tuned for part two of our discussion on GLP-1s where we welcome Dr. Rekha B. Kumar to the studio at RTW HQ.
FOLLOW US
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.
CHAPTERS
00:00 - Introductions
00:39 - Understanding the importance of GLP-1s
02:27 - GLPs in the cycle of obesity drug development
05:13 - Public and private company interest in obesity drugs
06:58 - Cost benefits of GLP-1s and their Impact on the healthcare system
10:30 - The value of GLP-1s in the investor space
12:36 - GLP-1s in the international market
16:12 - The expansion of large companies into GLP-1s
18:35 - Thoughts on recent investments and the potential of Kailera Therapeutics
19:52 - Outro and disclaimer
DISCLAIMER
This interview was given by Rod Wong, Managing Partner and Chief Investment Officer of RTW Investments, and moderated by Stephanie Sirota, Chief Business Officer, and Partner at RTW Investments. Statements reflect RTW’s views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results.
-
Sarah Boyce from Avidity Biosciences and Piratip Pratumsuwan from RTW Investments explore the strategic decisions and innovations that have driven Avidity's success. They cover her approach to overcoming the challenges of scaling a biotech company, the impact of Avidity’s groundbreaking work on treating rare genetic disorders, and Sarah’s vision for the future of RNA-based therapies.
PODCAST TEAM
Producer: Devon Leaver
Technical Director: Joseph Sebring
Editor: Dominique Guerra
Featuring: Sarah Boyce, President and CEO of Avidity Biosciences, and Piratip Pratumsuwan, Managing Director; Research Analyst at RTW Investments.
FOLLOW US
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.
CHAPTERS
00:00 - Introducing Sarah Boyce and Piratip Pratumsuwan
01:09 - Avidity Biosciences: Pioneering RNA therapeutics
02:20 - Joining Avidity: A bold decision
03:55 - Navigating challenges and embracing opportunities
12:00 - FSHD and Fortitude
18:21 - Looking Ahead: The future of RNA therapeutics
20:10 - Championing women in biotechnology
21:43 - Credits and disclaimer
DISCLAIMER
This interview and testimonial was given by Sarah Boyce, CEO of Avidity Biosciences, a company in which RTW has made an equity investment on behalf of its managed funds. No compensation was provided to Ms. Boyce.
-
Saknas det avsnitt?
-
Mark McKenna from Prometheus Biosciences and Josh Kennedy-Smith from RTW Investments tell us about the white-knuckle ride that is building a pharmaceutical start-up, their passion for providing better care solutions for patients, the recent deal with Merck and the power of a strong partnership with your investor.
Host: Josh Baldwin, RTW Investments
Featuring: Mark McKenna, CEO of Prometheus Biosciences and Josh Kennedy-Smith, Managing Director; Research Analyst of RTW Investments
